Treatment Of Oligohydramnios

Clinical Study Of Oligohydramnios (Khillat E Rahal)And Its Management With Unani Medicine - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/067475

Enrollment

Registered

2024-05-16

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O410- Oligohydramnios

Interventions

Intervention1: Darunaj aqrabi(Doronicum hookeri) Sharbat e anar Shirin: 1 gram sufoof e darunaj aqrabi with 20 ml sharbat e anar Shirin in morning with water Intervention2: Darunaj aqrabi(Doronicum ho

Eligibility

Inclusion criteria

Inclusion criteria: Both primi gravida and multigravida Age 18-35 years Gestational age 26 to 36 weeks Patients with AFI more than 6 cms to less than 10 cms

Exclusion criteria

Exclusion criteria: Pregnant women age more than 35 years AFI less than 6 cms Pre eclampsia Uncontrolled PIH Pregnant women systemic diseases like GDM, renal diseases, cardiac diseases, tuberculosis and etc Patients with bad obstetric history Foetal anomalies, leaking amniotic fluid

Design outcomes

Primary

Measure	Time frame
Increase the AFI and reduce the fetal complicationsTimepoint: Each patient give the oral medication of 20 days and check the AFI	—

Secondary

Measure	Time frame
To reduce maternal and fetal mortality and morbidity rateTimepoint: Each patients outcome depends on 20 days of oral medication and assessment will be done by AFI	—

Countries

India

Contacts

Public ContactDr Shaikh Azmatshirin

Govt Nizamia Tibbi College and General Hospital

syedaabidunnisa@gmail.com9492027082

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026